The company narrowed its full-year guidance as its blockbuster weight-loss drug soars in popularity.

Novo Nordisk reported forecast-beating third-quarter sales of its popular Wegovy weight-loss drug on Wednesday, reassuring investors worried that demand was slowing and it could lose the race in the fast-growing obesity drug market.

Novo Nordisk A/S’s sales of the blockbuster weight-loss drug Wegovy leapt last quarter as it became available in more countries, a relief for investors after rival Eli Lilly & Co. reported disappointing obesity sales last week.

Sales of Novo Nordisk’s (NVO) blockbuster weight loss drug Wegovy continue to soar, surpassing Wall Street expectations. The Danish pharma giant posted its third-quarter earnings report early Tuesday morning and boasted sales figures blowing past analysts’ projections.

Novo Nordisk is lifting curbs on prescriptions of its weight-loss drug Wegovy in the United States and is increasing supply in that market, its CEO said on Wednesday.

Novo Nordisk on Wednesday reported third quarter earnings broadly in line with expectations and narrowed its 2024 full-year growth guidance.

Semaglutide, the scientific name for Novo’s GLP-1 diabetes drug Ozempic and obesity drug Wegovy, has been on the shortage list for over two years, with different doses being listed in shortage at various times.

Novo Nordisk A/S’s Wegovy helped treat an obesity-associated liver disease in a late-stage trial, potentially adding to its status as a weight-loss medicine that can treat and prevent several other conditions.

Popular weight-loss drug Wegovy maker Novo Nordisk expects high demand and acceptance for its anti-obesity drug, when launched in India, a top executive said. The company is still "evaluating" the price of the drug,

A mixed sales report for Novo Nordisk’s GLP-1 megablockbuster drugs failed to quiet concerns Wednesday that investors may have overestimated the market for its new weight-loss and diabetes medicines.